Semaglutide 2.4 mg injection demonstrated significant weight loss versus placebo when added to intensive behavioural therapy

BAGSVÆRD, Denmark, Nov. 6, 2020 /PRNewswire/ -- Results of a phase 3a trial showed that investigational drug semaglutide 2.4 mg once-weekly subcutaneous as an adjunct to intensive behavioural therapy (IBT) demonstrated significantly more body weight loss compared to placebo plus IBT.[i] The STEP 3 phase 3a trial investigated the...

Read more: Semaglutide 2.4 mg injection demonstrated significant weight loss versus placebo when added to inten...

More Articles …

  1. New football simulator Football for Friendship World to be released on World Football Day
  2. FP Markets recognised as 'Best FX Broker Australia' for 2020
  3. Fuji Xerox Strengthens Synergies Within Fujifilm Group to Create Growth Globally-PR Newswire APAC
  4. Cellarity signs up with Excelra for GOSTAR database to enrich its drug discovery platform-PR Newswire APAC
  5. Cloud4C and SNP Ink Global Partnership Agreement-PR Newswire APAC
  6. Healthscope selects Adoreboard to improve Patient Experience in a Post-COVID World-PR Newswire APAC
  7. SOR Autonomous Security Drone Collaboration
  8. Hi-Chew goes bigger and better with hit social media campaign-PR Newswire APAC
  9. The Swedish battery technology company TEXEL signs agreement with Curtin University in Australia to develop next generation battery-PR Newswire APAC
  10. Maire Tecnimont Group's NextChem And Indian Oil Corporation Sign India's First Circular Economy MoU-PR Newswire APAC